阿立哌唑与富马酸喹硫平联用治疗精神分裂症的效果分析
|
摘要
目的 探讨阿立哌唑与富马酸喹硫平联合使用治疗精神分裂症的临床效果。方法 将收治的186例精神分裂症患者为研究对象,按治疗方案的不同分为3组,每组62例。A组使用阿立哌唑治疗,B组使用富马酸喹硫平治疗,C组使用阿立哌唑联合富马酸喹硫平治疗,比较3组临床疗效、CGI评分及不良反应发生情况。结果 C组治疗总有效率明显高于A组和B组,差异有统计学意义(P<0.05);C组CGI评分改善显著优于A组和B组,差异有统计学意义(P<0.05);3组均有多种类型的不良反应情况发生,但不良反应发生率经比较,差异无统计学意义(P>0.05)。结论 阿立哌唑联合富马酸喹硫平治疗精神分裂症的疗效较好,可有效改善症状,促进康复,且安全性可控,值得推广。
Objective To investigate the therapeutic effects of aripiprazole combined with quetiapine fumarate on schizophrenia. Methods A total of 186 patients with schizophrenia who were admitted and treated in our hospital were enrolled in thestudy,who were divided into three groups according to different treatment schemes, with 62 patients in each group. The patients in group A were treated by aripiprazole,and the patients in group B were treated by quetiapine fumarate,and the patients in group C were treated by aripiprazole combined with quetiapine fumarate. The clinical efficacy, CGI score and adverse reactions were observed and compared among the three groups.Results The total effective rate in group C was significantly higher than that in group A and group B(P<0.05).The CGI scores in group C were superior to those in group A and those in group B(P<0.05).There were many types of adverse reactions in the three groups, there were no significant differences in the incidence rates of adverse reactions among the three groups(P>0.05).Conclusion The therapeutic effects of aripiprazole combined with quetiapine fumarate on schizophrenia are satisfactory,which can effectively improve clinical symptoms, promote rehabilitation,with good safety,therefore,which is worthy of clinical promotion.
Objective To investigate the therapeutic effects of aripiprazole combined with quetiapine fumarate on schizophrenia. Methods A total of 186 patients with schizophrenia who were admitted and treated in our hospital were enrolled in thestudy,who were divided into three groups according to different treatment schemes, with 62 patients in each group. The patients in group A were treated by aripiprazole,and the patients in group B were treated by quetiapine fumarate,and the patients in group C were treated by aripiprazole combined with quetiapine fumarate. The clinical efficacy, CGI score and adverse reactions were observed and compared among the three groups.Results The total effective rate in group C was significantly higher than that in group A and group B(P<0.05).The CGI scores in group C were superior to those in group A and those in group B(P<0.05).There were many types of adverse reactions in the three groups, there were no significant differences in the incidence rates of adverse reactions among the three groups(P>0.05).Conclusion The therapeutic effects of aripiprazole combined with quetiapine fumarate on schizophrenia are satisfactory,which can effectively improve clinical symptoms, promote rehabilitation,with good safety,therefore,which is worthy of clinical promotion.
引文
1 Pankowski D,Kowalski J,Gawda L.The effectiveness of metacognitive training for patients with schizophrenia:a narrative systematic review of studies published between 2009 and 2015.Psychiatr Pol,2016,50:787-803.
2 Karakua-Juchnowicz H,Dzikowski M,Pelczarska A,et al.The brain-gut axis dysfunctions and hypersensitivity to food antigens in the etiopathogenesis of schizophrenia.Psychiatr Pol,2016,50:747-760.
3 李凌江.精神分裂症长期药物治疗的依从性.中华精神科杂志,2018,64:67-68.
4 李惠春.精神分裂症长期药物治疗的评估与监测.中华精神科杂志,2018,64:66-67.
5 孙志刚,王学义.精神分裂症认知功能缺陷的药物治疗研究进展.临床精神医学杂志,2017,28:140-142.
6 吴金丽.阿立哌唑的临床应用.医学信息,2018,32:42-45.
7 李志满.新型抗抑郁药联合喹硫平治疗难治性抑郁障碍的进展概述.齐齐哈尔医学院学报,2013,35:2739-2741.
8 戴云飞,肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较.临床精神医学杂志,2013,24:426-427.
9 刘豫鑫,王玉凤,杨莉.美国精神障碍诊断与统计手册第4版与国际疾病分类第10版诊断为多动综合征患儿的认知功能比较.中华精神科杂志,2004,50:103-106.
10 许梦蓓,单纯烁,郑国庆.精神疾病治疗进展(一):精神分裂症.医药导报,2017,36:1133-1137.
11 杨涛,唐鲁平,汪帅,等.精神分裂症住院患者社会支持、自尊现状及相关性研究.中国医药导报,2017,38:149-153.
12 吴冬薇.富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的临床研究.中国处方药,2018,17:77-78.
13 李永强,冯金河,乔兴菊.阿立哌唑与喹硫平治疗精神分裂症.河南科技大学学报(医学版),2017,36:135-136,139.
14 谭友才,胡敬群,张艳艳,等.阿立哌唑治疗男性精神分裂症的疗效及对糖脂代谢的影响.安徽医药,2018,22:961-964.
15 徐国栋.阿立哌唑的临床应用与其不良反应.中国卫生标准管理,2017,8:103-106.
16 陈虹.奥氮平联合富马酸喹硫平治疗精神分裂症的效果和安全性.中外医学研究,2017,15:69-70.
2 Karakua-Juchnowicz H,Dzikowski M,Pelczarska A,et al.The brain-gut axis dysfunctions and hypersensitivity to food antigens in the etiopathogenesis of schizophrenia.Psychiatr Pol,2016,50:747-760.
3 李凌江.精神分裂症长期药物治疗的依从性.中华精神科杂志,2018,64:67-68.
4 李惠春.精神分裂症长期药物治疗的评估与监测.中华精神科杂志,2018,64:66-67.
5 孙志刚,王学义.精神分裂症认知功能缺陷的药物治疗研究进展.临床精神医学杂志,2017,28:140-142.
6 吴金丽.阿立哌唑的临床应用.医学信息,2018,32:42-45.
7 李志满.新型抗抑郁药联合喹硫平治疗难治性抑郁障碍的进展概述.齐齐哈尔医学院学报,2013,35:2739-2741.
8 戴云飞,肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较.临床精神医学杂志,2013,24:426-427.
9 刘豫鑫,王玉凤,杨莉.美国精神障碍诊断与统计手册第4版与国际疾病分类第10版诊断为多动综合征患儿的认知功能比较.中华精神科杂志,2004,50:103-106.
10 许梦蓓,单纯烁,郑国庆.精神疾病治疗进展(一):精神分裂症.医药导报,2017,36:1133-1137.
11 杨涛,唐鲁平,汪帅,等.精神分裂症住院患者社会支持、自尊现状及相关性研究.中国医药导报,2017,38:149-153.
12 吴冬薇.富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的临床研究.中国处方药,2018,17:77-78.
13 李永强,冯金河,乔兴菊.阿立哌唑与喹硫平治疗精神分裂症.河南科技大学学报(医学版),2017,36:135-136,139.
14 谭友才,胡敬群,张艳艳,等.阿立哌唑治疗男性精神分裂症的疗效及对糖脂代谢的影响.安徽医药,2018,22:961-964.
15 徐国栋.阿立哌唑的临床应用与其不良反应.中国卫生标准管理,2017,8:103-106.
16 陈虹.奥氮平联合富马酸喹硫平治疗精神分裂症的效果和安全性.中外医学研究,2017,15:69-70.